Most Higher-Risk Adults Were Above the New LDL Cholesterol Goals

Retrospective: This article was published August 8, 2026, and looks back at a JAMA research letter published July 20, 2026.

A new cholesterol guideline is only useful if the gap between a person's measured LDL cholesterol and the guideline goal is visible. A JAMA analysis suggests that gap is large for many US adults at higher cardiovascular risk.

Researchers analyzed 2,313 adults ages 30 to 79 in the 2021 to 2023 National Health and Nutrition Examination Survey. With survey weighting, the sample represented an estimated 177.7 million US adults. The team assigned LDL cholesterol goals using the risk categories in the 2026 American College of Cardiology and American Heart Association dyslipidemia guideline.

The gap widened with risk

Among adults without established atherosclerotic cardiovascular disease, an estimated 32.2% had LDL cholesterol above the guideline goal for their risk group. The estimate was 9.9% among adults classified as low risk, 63.6% among those at borderline or intermediate risk, and 82.7% among those at high risk.

Among adults who already had atherosclerotic cardiovascular disease, an estimated 79.6% had LDL cholesterol above goal.

The treatment gap was also substantial. Among people above goal, the researchers estimated that 76.1% in the primary-prevention group and 37.6% in the secondary-prevention group were not receiving lipid-lowering therapy. Treatment use was self-reported, so the study cannot show why an individual participant was untreated or above goal.

What the study does and does not show

This was a cross-sectional analysis of nationally representative survey data. It estimated how common above-goal LDL cholesterol was at one point in time. It did not test an intervention, prove that every participant should receive medication, or measure whether a specific treatment plan would improve an individual's outcome.

The analysis also applied risk-based LDL goals. That matters because the same LDL result can have different implications depending on cardiovascular history and estimated risk. The study is evidence of a population-level measurement and treatment gap, not a diagnosis for any reader.

Where lab testing fits

A lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. It supplies the measured values that clinicians can interpret alongside age, blood pressure, smoking, diabetes, cardiovascular history, and other risk information.

The useful takeaway is simple: LDL goals became more specific in the 2026 guideline, but the JAMA analysis found that many higher-risk adults were still above them. Knowing the number is the beginning of the conversation, not the treatment decision.

This article is editorial commentary and is not medical advice. It has not been reviewed by a physician and should not be used to make decisions about diagnosis, cholesterol medication, cardiovascular care, or testing frequency.